Eli Lilly and Company: all 2,262 studies
Page 18 of 23. Open to participants first (177), then studies with results posted, then the rest; newest registration first within each.
- FAPi Radioligand OpeN-Label, Phase 1 Study to Evaluate Safety, Tolerability and DosImetry of [Lu-177]-PNT6555; A Dose Escalation Study for TReatment of Patients With Select Solid Tumors (FRONTIER)TerminatedNCT05432193Phase 1
- A Study of LY3532226 in Participants With Type 2 Diabetes MellitusCompletedNCT05407961Phase 1
- A Study of VERVE-101 in Patients With Familial Hypercholesterolemia and Cardiovascular DiseaseCompletedNCT05398029Phase 1
- A Single-Ascending and Repeated Dose Study of LY3849891 in Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)CompletedNCT05395481Phase 1
- A Study of LY3541105 in Healthy and Overweight ParticipantsCompletedNCT05380323Phase 1
- A Study of LY3457263 Alone and in Combination With Dulaglutide (LY2189265) in Participants With Type 2 DiabetesCompletedNCT05377333Phase 1
- Single Ascending Dose Study With BPL-003 in Healthy SubjectsCompletedNCT05347849Phase 1
- A Study of Single and Repeated Doses of LY3556050 in Healthy ParticipantsCompletedNCT05341102Phase 1
- A Study of LY3549492 in Participants With Type 2 Diabetes Mellitus (T2DM)CompletedNCT05327595Phase 1
- A Study of LOXO-783 in Patients With Breast Cancer/Other Solid TumorsActive, not recruitingNCT05307705Phase 1
- Safety and Immunogenicity of CRV-101 Vaccine for the Prevention of Herpes Zoster in Adults Aged 50 Years and OlderActive, not recruitingNCT05304351Phase 2
- A Study of LY3841136 in Healthy and Overweight ParticipantsCompletedNCT05295940Phase 1
- A Study of LY3857210 in Healthy ParticipantsCompletedNCT05292040Phase 1
- A Study of LOXO-260 in Cancer Patients With a Change in a Particular Gene (RET) That Has Not Responded to TreatmentCompletedNCT05241834Phase 1
- Expanded Access for LOXO-260 in Participants With Cancer Caused by an Abnormal RET Gene That Did Not Respond/is no Longer Responding to Treatment With a Type of Drug Called a RET InhibitorNo longer availableNCT05225259
- A Study of LY3871801 in Healthy ParticipantsCompletedNCT05222399Phase 1
- Study of the Effects of Itraconazole and Carbamazepine on LY3410738 in Healthy ParticipantsTerminatedNCT05205447Phase 1
- Expanded Access Program for Pirtobrutinib for Participants With B-Cell CancerApproved for marketingNCT05172700
- A Study of Two Formulations (Both Refrigerated and Room Temperature) Using an Autoinjector Device in Healthy ParticipantsCompletedNCT05154968Phase 1
- A Study of LY3541860 in Healthy Japanese and Non-Japanese ParticipantsCompletedNCT05042310Phase 1
- A Study of LY3473329 in Healthy Japanese ParticipantsCompletedNCT05038787Phase 1
- Single Ascending Dose Study With 5-MeO-DMT in Healthy SubjectsCompletedNCT05032833Phase 1
- A Study of Oral Ibogaine in Opioid WithdrawalCompletedNCT05029401Phase 1/2
- A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)Active, not recruitingNCT05026866Phase 3
- Study of Oral LOXO-338 in Patients With Advanced Blood CancersCompletedNCT05024045Phase 1
- A Study of LY3361237 in Participants With PsoriasisCompletedNCT04975295Phase 1
- A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)Active, not recruitingNCT04965493Phase 3
- A Study of LY3209590 on Low Blood Sugar in Participants With Type 2 Diabetes MellitusCompletedNCT04957914Phase 1
- Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)Active, not recruitingNCT04956640Phase 1/2
- A Study of LY3532226 in Healthy ParticipantsCompletedNCT04923269Phase 1
- A Study of LY3819469 in Healthy ParticipantsCompletedNCT04914546Phase 1
- Phase 1b Study in Patients With Short-Lasting Unilateral Neuralgiform Headache Attacks (SUNHA)TerminatedNCT04905121Phase 1
- A Study of A Novel Approach to Titrate Basal Insulin (LY2963016) in Participants With Type 2 DiabetesWithdrawnNCT04864977Phase 4
- A Device Study in Healthy ParticipantsCompletedNCT04848402Phase 1
- A Study of LY3461767 in Participants With Chronic Heart Failure With Reduced Ejection FractionCompletedNCT04840914Phase 1
- A Study of LY3437943 in Japanese Participants With Type 2 Diabetes Mellitus (T2DM)CompletedNCT04823208Phase 1
- A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)Active, not recruitingNCT04819100Phase 3
- A Study of LY3540378 in Healthy ParticipantsCompletedNCT04768855Phase 1
- A Study of Two Different Formulations of LY3209590 in Healthy ParticipantsCompletedNCT04768842Phase 1
- A Study of LY3549492 in Healthy ParticipantsCompletedNCT04758234Phase 1
- Early Clinical Evaluation of 18F-LY3546117 in Tumor ImagingStatus unknownNCT04721756Early Phase 1
- A Study of Continuous Heart Rate Monitoring in Healthy ParticipantsCompletedNCT04682184Not applicable
- A Study of Glucose Control in Participants With Type 1 and Type 2 DiabetesWithdrawnNCT04667182
- Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)Active, not recruitingNCT04662255Phase 3
- A Study of LY3041658 in Healthy ParticipantsCompletedNCT04653168Phase 1
- A Study of LY3537031 in Healthy ParticipantsCompletedNCT04648865Phase 1
- Long-term Study of ADVM-022 in Neovascular (Wet) AMD [OPTIC-EXT]Active, not recruitingNCT04645212
- A Study of LY3561774 in Participants With DyslipidemiaCompletedNCT04644809Phase 1
- A Study of LY3457263 in Healthy Participants and Participants With Type 2 DiabetesCompletedNCT04641312Phase 1
- A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic MigraineActive, not recruitingNCT04616326Phase 3
- Expanded Access Program to Provide Bamlanivimab (LY3819253) for the Treatment of COVID-19No longer availableNCT04603651
- Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 MutationsActive, not recruitingNCT04603001Phase 1
- A Study of LY3537021 in Healthy Participants and Participants With Type 2 Diabetes MellitusCompletedNCT04586907Phase 1
- Study of MORF 057 to Evaluate Single and Multi Ascending Doses in Healthy VolunteersCompletedNCT04580745Phase 1
- Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 MutationsActive, not recruitingNCT04521686Phase 1
- A Study of an Insulin Management System in Participants With Type 1 or Type 2 DiabetesCompletedNCT04484779Not applicable
- A Study of LY3473329 in Healthy ParticipantsCompletedNCT04472676Phase 1
- A Study of Mirikizumab (LY3074828) in Participants With Ulcerative ColitisWithdrawnNCT04469062Phase 3
- A Study of LY3372993 in Participants With Alzheimer's Disease (AD) and Healthy ParticipantsCompletedNCT04451408Phase 1
- Phase 1/2 Clinical Trial of PR001 in Infants With Type 2 Gaucher Disease (PROVIDE)Active, not recruitingNCT04411654Phase 1/2
- Phase 1/2 Clinical Trial of LY3884963 in Patients With Frontotemporal Dementia With Progranulin Mutations (FTD-GRN)Active, not recruitingNCT04408625Phase 1/2
- A Study of the Effects of Multiple Doses of LY3372689 on the Brain in Healthy ParticipantsCompletedNCT04392271Phase 1
- A Study of LY3461767 in Healthy ParticipantsCompletedNCT04352114Phase 1
- A Study of LY3209590 in Japanese Participants With Type 2 Diabetes MellitusCompletedNCT04276428Phase 1
- A Study to Evaluate LY3154207 on the Brain of Healthy ParticipantsCompletedNCT04258826Phase 1
- A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial CancerActive, not recruitingNCT04188548Phase 1
- A Study of LY900027 Given by Insulin Pump to Participants With Type 1 Diabetes MellitusCompletedNCT04161976Phase 1
- A Study of LY3200882 and Pembrolizumab in Participants With Advanced CancerWithdrawnNCT04158700Phase 1/2
- A Study of LY3556050 in Healthy ParticipantsCompletedNCT04156750Phase 1
- A Safety Study of LY3462817 and LY3509754 in Participants With PsoriasisTerminatedNCT04152382Phase 1
- A Study of LY3437943 in Participants With Type 2 Diabetes Mellitus (T2DM)CompletedNCT04143802Phase 1
- Phase 1/2a Clinical Trial of PR001 (LY3884961) in Patients With Parkinson's Disease With at Least One GBA1 Mutation (PROPEL)Active, not recruitingNCT04127578Phase 1/2
- A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory NeuroblastomaActive, not recruitingNCT04106219Phase 1
- A Safety Study of LY3372689 in Healthy ParticipantsCompletedNCT04106206Phase 1
- A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With Systemic Juvenile Idiopathic Arthritis (sJIA)Active, not recruitingNCT04088396Phase 3
- A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Therapies in Japanese Participants With Advanced CancerCompletedNCT04071262Phase 1
- A Study of LY3475766 in Healthy ParticipantsCompletedNCT04052594Phase 1
- A Study of LY900020 in Healthy Chinese ParticipantsCompletedNCT04047940Phase 1
- A Study of LY3214996 in Healthy ParticipantsCompletedNCT04033341Phase 1
- Olaratumab (LY3012207) Patient Access for Soft Tissue SarcomaApproved for marketingNCT03994627
- A Study of Abemaciclib (LY2835219) in Participants With HR+, HER2- Advanced Breast CancerWithdrawnNCT03988114Phase 4
- A Study of LY3295668 Erbumine in Participants With Breast Cancer That Has Spread to Other Parts of the BodyCompletedNCT03955939Phase 1
- A Study of the Effects of LY3372689 on the Brain in Healthy ParticipantsCompletedNCT03944031Phase 1
- A Drug Interaction Study of LY3154207 in Healthy ParticipantsCompletedNCT03942029Phase 1
- A Study of LY3361237 in Participants With Systemic Lupus ErythematosusCompletedNCT03933943Phase 1
- A Study of LY3305677 in Participants With Type 2 DiabetesCompletedNCT03928379Phase 1
- A Study of Different Injectable Formulations of LY3375880 in Healthy ParticipantsCompletedNCT03913260Phase 1
- Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) ActivationApproved for marketingNCT03906331
- A Study of LY3295668 Erbumine in Participants With Extensive-stage Small-Cell Lung CancerCompletedNCT03898791Phase 1
- A Study of an Automated Insulin Delivery System in Adult Participants With Type 1 DiabetesCompletedNCT03890003Not applicable
- A Study of an Automated Insulin Delivery System in Adult Participants With Type 1 Diabetes MellitusCompletedNCT03849612Not applicable
- A Study of an Automated Insulin Delivery System in Adult Participants With Type 1 Diabetes Mellitus During Meal ChallengesCompletedNCT03848767Not applicable
- A Safety Study of LY3437943 Given as a Single Injection in Healthy ParticipantsCompletedNCT03841630Phase 1
- Safety, Tolerability, and Immunogenicity of CRV-101 in Healthy Adult SubjectsCompletedNCT03820414Phase 1
- A Safety Study of LY3372689 Given By Mouth to Healthy ParticipantsCompletedNCT03819270Phase 1
- An Interaction Study of LY3200882 in Healthy ParticipantsCompletedNCT03792139Phase 1
- Named Patient Use Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast CancerApproved for marketingNCT03763604
- A Study of Technology to Improve Glucose Control in Participants With Type 1 DiabetesCompletedNCT03758430
- A Study of LY3454738 in Healthy Participants and Participants With Atopic DermatitisCompletedNCT03750643Phase 1
- Study of LY3074828 in Healthy ParticipantsCompletedNCT03748940Phase 1